Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy
This is a phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy.
Cancer
DRUG: TLC178
Maximum tolerated dose (MTD) determination, To determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) ofintravenous LipoVNB given every 4 weeks (Q4W) in patients with advanced malignancies., 4 weeks
Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of vinorelbine[, Area under the plasma concentration time curve from zero (predose) extrapolated to infinity, from day 1 to day 29|Pharmacokinetics (PK) parameters of AUC (0-inf) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine, Area under the plasma concentration time curve from zero (predose) extrapolated to infinity, from day 1 to day 29|Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration ofvinorelbine, Area under the plasma concentration time curve from zero (predose) to the time of the lastquantifiable concentration, from day 1 to day 29|Pharmacokinetics (PK) parameters of AUC(0 - last) calculated by plasma concentration of majormetabolite, 4-O-deacetylvinorelbine, Area under the plasma concentration time curve from zero (predose) to the time of the lastquantifiable concentration, from day 1 to day 29|Pharmacokinetics (PK) parameters of Cmax calculated by plasma concentration of vinorelbine, Maximum plasma concentration observed, from day 1 to day 29|Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of vinorelbine, Time of Cmax, from day 1 to day 29|Pharmacokinetics (PK) parameters of tmax calculated by plasma concentration of major metabolite,4-O-deacetylvinorelbine, Time of Cmax, from day 1 to day 29|Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of vinorelbine, Apparent terminal half life, from day 1 to day 29|Pharmacokinetics (PK) parameters of t1/2 calculated by plasma concentration of 4-O-deacetylvinorelbine, Apparent terminal half life, from day 1 to day 29|Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of vinorelbine, Mean residence time extrapolated to infinity, from day 1 to day 29|Pharmacokinetics (PK) parameters of MRT(0-inf) calculated by plasma concentration of 4-O-deacetylvinorelbine, Mean residence time extrapolated to infinity, from day 1 to day 29|Dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of LipoVNB, single and multiple dose effect, up to 6 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03, treatment related AE, up to 6 months|Incidence of Treatment-Emergent Adverse Events, TEAE percentage, up to 6 months|LipoVNB antitumor activity assessed by response rate, antitumor response rate, up to 6 months|LipoVNB antitumor activity assessed by duration of response, antitumor efficacy, up to 6 months|Progression free survival (PFS) of patients with advanced malignancies treated with LipoVNB, PFS, up to 6 months
Protocol No: TLC178A1001

Name of Finished Product: LipoVNB (Liposomal Vinorelbine Tartrate)

Title of Study:

Phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy.

Study duration:

Every patient will have a treatment period of 4-week cycles until completion of 6 cycles, progression of disease or intolerance, withdrawal of consent or Investigator's judgment, whichever occurs first.